GlassScriptPhysician profile
Laura R Nash
NPI 1881990604
$1,515.81
in general payments reported to CMS, 2019-2025
21 companies · $667 in 2025
The $667 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.53 · 2021: $61.88 · 2022: $144 · 2023: $155 · 2024: $422 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $281.58 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $262.46 | 2023-2025 | |
| Lilly USA, LLC | $175.88 | 2024-2025 | Kisunla, Mounjaro |
| Abbvie INC. | $158.32 | 2023-2025 | |
| Glaxosmithkline, LLC. | $143.99 | 2022-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $82.17 | 2022 | |
| Abbott Laboratories | $68.92 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $51.50 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $47.26 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $36.50 | 2024 | Camzyos |
| Biohaven Pharmaceuticals, INC. | $28.72 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.54 | 2025 | Airsupra |
| Phathom Pharmaceuticals, INC. | $20.48 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $19.50 | 2025 | Zenpep |
| Boston Scientific Corporation | $19.44 | 2025 | Watchman Access System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $18.88 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.79 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $16.87 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Ars Pharmaceuticals Operations, INC. | $16.10 | 2025 | Neffy |
| Dexcom, INC. | $14.78 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $14.13 | 2025 | Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.